Oral agent therapy in the treatment of type 2 diabetes.
Feinglos
M N
MN
Division of Endocrinology and Metabolism, Duke University Medical Center 27710, USA. feing002@mc.duke.edu
Bethel
M A
MA
D000284:Administration, Oral; D001645:Biguanides / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D017211:Treatment Failure
D001645:Biguanides; D004791:Enzyme Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds